Joint Pain Injections Market Size & Share 2026-2035

Joint Pain Injections Market Size

The global joint pain injections market is estimated at USD 6.1 billion in 2025 and is projected to reach USD 12.8 billion by 2035, expanding at a 7.8% CAGR.

The market had reached approximately USD 5.7 billion in 2024, up from approximately USD 5.1 billion in 2022. Demand is tied primarily to the expanding osteoarthritis (OA) population, particularly patients seeking symptom control before considering joint replacement or other invasive interventions.

Musculoskeletal conditions affect an estimated 1.71 billion people globally and are a leading source of disability. OA is the central demand pool for intra-articular injections: the World Health Organization estimated that 528 million people were living with OA in 2019, with the knee the most commonly affected site. ^{[1]World Health Organization, Musculoskeletal health, 2022, who.int} A 2025 analysis estimated approximately 607 million prevalent OA cases in 2021 and reported that high-body-mass-index-attributable OA disability-adjusted life years increased from 1.45 million in 1990 to 4.42 million in 2021. ^{[2]Arthritis Research & Therapy, Global, regional and national burden of osteoarthritis attributable to high body mass index from 1990 to 2021, 2025, link.springer.com}

Growth to 2035 is expected to be driven by the interaction of a large OA population, increasing acceptance of minimally invasive interventions, and higher-value product innovation. HA will remain the revenue anchor because it has the deepest reimbursement infrastructure and broadest installed prescriber base. PRP, with an approved CAGR of 8.4%, has greater growth potential but must convert clinical evidence into more consistent protocols and payer confidence.

The strongest upside lies in products that improve the clinical and economic proposition of an injection episode: single-injection HA, extended-release corticosteroids, standardized PRP systems, and combination or regenerative therapies. Geographic expansion will be most meaningful where specialist capacity and reimbursement are improving simultaneously, rather than in markets where patient demand rises without a viable payment pathway.

HA remains protected by physician familiarity and reimbursement infrastructure, while PRP is gaining clinical credibility without equivalent payment support. This creates two parallel markets: a reimbursed, protocol-driven HA and corticosteroid market, and a more fragmented PRP market where providers carry greater responsibility for pricing, patient education, and outcome consistency. The distinction matters for manufacturers because product innovation alone does not guarantee adoption; the innovation must also fit coding, evidence, and site-of-care workflows.

Regulatory tightening has a similarly mixed effect. Requirements under U.S. and European frameworks raise development and documentation costs, but they can also reduce the ability of lightly resourced suppliers to compete on price alone., Established suppliers with robust quality systems are therefore positioned to benefit from a market that grows through premiumization and procedural migration, rather than through undifferentiated unit expansion.

Key Drivers

Rising Prevalence of Osteoarthritis and Musculoskeletal Disorders

OA creates a recurring pool of patients who require pain management over extended periods, rather than a single acute-care episode. The anticipated 74.9% increase in global knee OA burden through 2050 gives the market a long-duration volume base. ^{[3]PubMed, Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050, 2023, pubmed.ncbi.nlm.nih.gov} Rising obesity is particularly important because it increases mechanical loading and inflammation-related risk while broadening disease incidence beyond the oldest population groups.

The effect is strongest where patients can access imaging, orthopedic consultation, and reimbursed procedures. North America and Japan have established pathways, while India and China offer a larger longer-term volume opportunity as specialty capacity expands. Product suppliers that can serve both mature reimbursement markets and lower-cost emerging markets will be better placed to capture this demographic expansion.

Growing Adoption of Minimally Invasive and Non-Surgical Therapies

Injections occupy a clinically useful position between conservative management and arthroplasty. Patients may select injection therapy to manage symptoms while delaying surgery, assessing surgical eligibility, or maintaining mobility during rehabilitation and weight-management efforts. The economic proposition depends on the treatment setting: hospital outpatient care, specialist clinics, and ambulatory surgical centers have different administrative costs and patient convenience profiles.

Single-injection HA and extended-release corticosteroids can be especially attractive when repeat visits are a barrier. The growth of ultrasound-guided procedures further supports use in anatomically difficult joints, though it also raises the importance of clinician capability and equipment availability. Providers that integrate diagnostics, guided injection, and follow-up can capture procedural efficiency benefits that product suppliers alone cannot create.

Advancements in Biologic and Regenerative Therapies

PRP is advancing because clinical evidence increasingly suggests durable benefit for selected knee OA patients, while standardized processing platforms seek to reduce historic variability. The category's near-term growth is not assured by efficacy findings alone. Payers require evidence that is comparable across devices and protocols, and clinics require workflows that can deliver predictable outcomes without undermining patient throughput.

Combination products may provide a more practical path to differentiation than entirely new therapeutic classes. HA-drug conjugates and HA-corticosteroid combinations seek to combine lubricant, anti-inflammatory, and dosing-convenience benefits. JOYCLU's Japanese commercialization demonstrates that novel HA-based chemistry can reach market when its clinical proposition and regulatory positioning are sufficiently clear. ^{[4]Ono Pharmaceutical, Launch of JOYCLU for osteoarthritis, 2021, ono-pharma.com}

Rising Awareness and Healthcare Access

Awareness expands demand only when patients can progress from recognizing chronic joint pain to receiving specialist evaluation and treatment. In the United States, a National Poll on Healthy Aging found that approximately 70% of adults aged 50 to 80 reported joint pain. This highlights a substantial pool that may seek intervention but does not itself guarantee procedural conversion.

Access improvements will be most commercially relevant in Asia Pacific, Latin America, and the Middle East, where private orthopedic capacity and public musculoskeletal-care investment are developing unevenly. Suppliers will need differentiated approaches: premium single-injection or PRP offerings may fit private channels, while public systems will emphasize affordability, local registration, and evidence aligned with reimbursement requirements.

Key Restraints

Risk of Adverse Reactions and Variable Efficacy

Clinical evidence is not equally consistent across modalities, disease stages, and protocols. HA remains subject to divergent guideline positions, even though evidence reviews identify patient groups for whom clinically meaningful benefit is more likely. ^{[5]PubMed Central, EUROVISCO consensus guidelines for the use of hyaluronic acid viscosupplementation in knee osteoarthritis, 2024, pmc.ncbi.nlm.nih.gov} This creates a payer and prescriber challenge: broad category claims are less persuasive than evidence tied to OA severity, dosing schedule, and treatment history.

Corticosteroids have a well-established short-term role, but repeated administration must be managed carefully. PRP faces a different limitation: variability in preparation and administration makes it difficult to translate favorable trials into uniform real-world outcomes. The market consequence is a continuing need for physician selection criteria, protocol standardization, and post-treatment outcome documentation.

Stringent Regulatory Requirements

Regulatory requirements slow product development and add compliance costs, particularly for high-risk medical devices and advanced biological products. The U.S. discussion of HA classification and the implementation burden associated with EU MDR show why regulatory strategy cannot be separated from commercial strategy.,

For large companies, compliance investment can create a defensible market position. For small suppliers, it can delay product launches, limit geographic expansion, or force dependence on distributors and contract manufacturers. The restraint is therefore not simply a drag on market growth; it also changes the relative competitiveness of companies with different regulatory capabilities.

The more variable drivers are procedure migration, PRP adoption, and healthcare access. These depend on reimbursement, provider capacity, and evidence translation. A PRP system with strong clinical support may still remain a niche clinic offering if payment remains out of pocket. Conversely, an HA product with modest formulation differentiation can gain material volume when it secures a favorable payer contract or reduces repeat-visit requirements.

The restraints reinforce this split. Evidence variability creates near-term friction in guidelines and patient counseling, while regulatory requirements reshape the supplier base over a longer cycle.,, The resulting market is unlikely to reward companies solely for participating in the broad OA trend. The strongest positions will combine evidence-generation capability, reimbursement execution, and manufacturing quality systems that allow differentiated products to remain available when regulatory and payer standards tighten.

Joint Pain Injections Market Segment Analysis

By Injection Type

HA injections account for 64.90% of global revenue in 2025, equivalent to approximately USD 3,946.80 million. Their dominant position reflects established use in knee OA, broad provider familiarity, and a product architecture that accommodates five-, three-, and single-injection regimens. The category's commercial differentiation increasingly centers on convenience, product origin, molecular characteristics, and payer access rather than basic category presence.

Single-injection formulations can reduce the operational burden associated with repeated appointments. This is relevant to both patients and providers, particularly in high-throughput clinics. Ferring's EUFLEXXA is positioned as a non-avian HA formulation, while Anika, Bioventus, Sanofi, OrthogenRx, and Zimmer Biomet compete across regimen length and product characteristics.,,

Corticosteroid injections represent 22.50% of 2025 revenue, or approximately USD 1,368.31 million. The segment benefits from low relative cost, rapid onset, and established reimbursement. Pfizer's Depo-Medrol remains a major product within the corticosteroid portfolio, while ZILRETTA provides an extended-release alternative for OA knee pain. ^{[6]DailyMed, ZILRETTA: triamcinolone acetonide extended-release injectable suspension, prescribing information, dailymed.nlm.nih.gov}

The category's limitation is its treatment-frequency profile. Repeated use is clinically managed with caution, which limits the ability to expand revenue through frequent repeat administration. This makes extended-release formulations commercially important: they seek to increase differentiation without relying solely on a higher procedure count.

PRP accounts for 9.10% of market revenue, or approximately USD 553.40 million, in 2025 and is projected to grow at an 8.4% CAGR. Its growth is supported by evidence indicating meaningful longer-term pain and functional outcomes in selected knee OA populations. However, PRP remains commercially fragmented because preparation systems and clinical protocols differ materially.

Arthrex, EmCyte Corporation, and Stryker participate through PRP and orthobiologic processing platforms. Their competitive advantage depends on standardizing preparation, supporting clinical education, and fitting into clinic or ASC workflows. As PRP continues to be financed largely outside routine reimbursement, providers' ability to communicate value and manage patient expectations remains central to adoption.

Other injection types account for 3.50% of revenue, or approximately USD 212.85 million, in 2025. This group includes HA-drug conjugates, HA-corticosteroid combinations, and emerging cell-based and regenerative approaches. The segment is small but strategically important because it contains many of the products that could alter the category's pricing and clinical differentiation.

JOYCLU and Ciplostem illustrate distinct routes to expansion: the former combines HA with an anti-inflammatory agent, while the latter introduces an allogeneic cell-therapy proposition for knee OA. ^{[7]Cipla, Cipla launches Ciplostem for knee osteoarthritis, 2025, cipla.com} Commercial scale will depend on regulatory clarity, reproducible manufacturing, and evidence that supports use beyond narrowly selected patients.

By Joint Type

The knee segment accounts for 74.14% of revenue, or approximately USD 4,508.72 million, in 2025 and is projected to reach approximately USD 9.6 billion by 2035. This concentration reflects the global prevalence of knee OA, the availability of products specifically indicated for the knee, and comparatively established injection technique and reimbursement pathways.

The knee is also the primary evidence-development arena for HA, corticosteroid, PRP, and emerging regenerative therapies. Consequently, suppliers can often leverage knee data to build physician familiarity before pursuing expansion into more technically complex joints.

Shoulder and elbow applications represent 16.77% of revenue, or approximately USD 1,019.84 million, and are expected to grow at a 7.4% CAGR. These applications involve a broader mix of OA, soft-tissue, tendon-related, and sports-medicine indications than knee injection therapy. Procedural accuracy and imaging capability carry greater weight, which favors specialist practices with ultrasound expertise.

The segment offers a route for product expansion but has less standardized reimbursement and evidence than knee OA. Suppliers must therefore support provider training and indication-specific evidence rather than assuming knee-market success translates automatically.

Ankle and hip applications account for 5.93% of revenue, or approximately USD 360.62 million, in 2025. Hip injections frequently require image guidance because of joint depth and surrounding neurovascular structures. This increases procedural complexity and limits high-volume use compared with the knee.

Ankle injection demand includes post-traumatic OA and sports-medicine care. These joints can support premium, specialist-led treatment but are less likely to drive broad market volume without expanded evidence and favorable site-of-care economics.

Other joint types account for 3.16% of revenue, or approximately USD 192.17 million, in 2025. They include small joints and other specialized pain-management applications. This segment is heterogeneous, making standardized product positioning more difficult. Its value lies in extending physician relationships and product utilization across musculoskeletal practices rather than generating knee-scale demand.

By End Use

Hospitals account for 56.55% of 2025 revenue, or approximately USD 3,439.01 million. Their leading role reflects integrated care pathways involving imaging, orthopedic consultation, rheumatology, and procedural administration. Hospitals also remain important within buy-and-bill models for reimbursed HA products.

The hospital channel favors suppliers that can meet formulary, purchasing, documentation, and supply-reliability requirements. Scale is valuable, but it also increases exposure to centralized purchasing decisions and reimbursement-policy revisions.

Orthopedic and pain clinics account for 26.70% of revenue, or approximately USD 1,623.72 million, and are projected to expand at an 8.2% CAGR. Their growth reflects demand for specialist access, faster scheduling, and lower-overhead procedural settings. Clinics are also particularly important for PRP because they can integrate patient-paid treatment, blood processing, imaging, and follow-up within one practice.

This channel rewards direct commercial relationships and practical workflow support. OrthogenRx's direct-purchase approach for GenVisc 850 and TriVisc illustrates how suppliers can serve clinics seeking alternatives to complex reimbursement administration.

ASCs account for 9.80% of market revenue, or approximately USD 595.97 million, in 2025. They benefit from the broader movement of appropriate orthopedic procedures into lower-cost outpatient settings. Single-dose products and streamlined PRP systems are particularly compatible with ASC workflow because they minimize storage, preparation, and repeat-visit requirements.

Other end users account for 6.95% of market revenue, or approximately USD 422.65 million, in 2025. This category includes specialized outpatient, rehabilitation, and research settings. It is less concentrated than hospitals or orthopedic clinics and is shaped by local practice authority and reimbursement conditions.

This division has direct consequences for portfolio strategy. HA suppliers cannot rely on installed demand alone because single-injection convenience, payer access, and product differentiation can shift utilization within the category. PRP suppliers face a different task: they must convert clinical promise into repeatable workflows and a credible patient-paid value proposition., The commercial winner is not necessarily the company with the broadest product catalog, but the one that matches a modality to the economics of the care setting.

The knee remains the essential competitive battleground because it offers the largest addressable population, strongest clinical-evidence base, and most developed procedural infrastructure. Other joints provide targeted growth opportunities but require more specialized delivery. The shift toward clinics and ASCs also increases the importance of direct provider relationships, inventory simplicity, and procedure-standardization support relative to traditional hospital-only selling models.

Joint Pain Injections Market Regional Analysis

North America

North America accounts for 47.08% of global market revenue in 2025, or approximately USD 2,863.10 million. The United States contributes approximately USD 2.6 billion, supported by a large OA population, established specialist infrastructure, and Medicare-linked reimbursement for eligible HA procedures. ^{[8]Centers for Disease Control and Prevention, Osteoarthritis, 2024, cdc.gov}

The region's size does not eliminate commercial risk. Reimbursement methodology, local coverage decisions, and payer formulary contracts can shift product economics quickly. Bioventus' Aetna Medicare Advantage agreement illustrates the importance of access strategy, while the 2022 reimbursement change illustrates the risk of relying heavily on a single payment framework., Canada supports stable demand but typically has more constrained provincial funding and slower access to premium injection formats.

Europe

Europe represents approximately USD 1.5 billion of market revenue in 2025. Demand is supported by aging populations and established orthopedic care, but the market remains fragmented by national reimbursement and health-technology-assessment practices. EU MDR imposes a common regulatory framework, while payment decisions remain substantially national or regional.

This combination favors companies able to sustain robust regulatory documentation while adapting commercial evidence to country-specific payers and clinical guidelines. Germany, France, the United Kingdom, Italy, and Spain remain the largest opportunities, but their access conditions are not interchangeable. Suppliers should avoid treating Europe as one reimbursement market even where the regulatory requirements are increasingly harmonized.

Asia Pacific

Asia Pacific is projected to be the fastest-growing region, at an 8.3% CAGR. China and India offer the largest long-term patient pools, while Japan is the region's most developed market for approved injectable therapies. India's Ciplostem launch and Japan's JOYCLU commercialization demonstrate that Asia Pacific can also be a source of product innovation and early commercialization, not merely an export destination. .

The region contains divergent market models. Japan's reimbursed and regulated environment rewards clinical and regulatory rigor. India and China combine substantial volume potential with varying affordability, specialist access, and local-registration requirements. Australia and South Korea offer mature specialist markets where differentiated products can gain access through product approval and provider adoption.

Latin America

Latin America is expanding from a comparatively smaller base, led by Brazil. The region's opportunity is linked to the development of private orthopedic care alongside public-sector demand for affordable musculoskeletal management. Bioventus selected Pfizer as its exclusive DUROLANE distribution partner in Brazil, demonstrating the importance of established local commercialization capability.

Brazil's regulatory requirements and distribution complexity can favor international suppliers that partner with established local networks. Mexico and Argentina are secondary opportunities, but purchasing power and reimbursement limitations require product portfolios that span premium and accessible treatment options.

Middle East and Africa

The Middle East and Africa region is heterogeneous. Gulf markets can support premium HA and selected PRP procedures through well-funded private and public hospitals, while many African markets remain constrained by specialist capacity and limited reimbursement. Saudi Arabia's 2024 authorization of MBI's ArtiAid and ArtiAidPlus illustrates ongoing regulatory activity in intra-articular products.

The most practical growth route is concentrated rather than region-wide. Manufacturers should prioritize Saudi Arabia, the United Arab Emirates, and South Africa, where orthopedic infrastructure and purchasing capacity are more developed, while recognizing that broad access across sub-Saharan Africa will remain limited by healthcare-system constraints.

Asia Pacific's 8.3% CAGR represents a different opportunity. Growth is likely to be driven by expanding specialist access, increasing affordability in selected urban markets, and the development of locally relevant products and regulatory pathways. Japan's commercialization of JOYCLU and India's launch of Ciplostem show that regional innovation is becoming commercially relevant alongside imported HA and PRP systems.,

Europe sits between these models. Its mature demand and EU MDR requirements can support established suppliers, but national reimbursement fragmentation limits the effectiveness of a single regional launch strategy. The most durable global strategies will therefore combine North American reimbursement discipline, European regulatory readiness, and Asia-Pacific market-development capability rather than assuming that one product, price, or evidence package can travel unchanged across regions.

Joint Pain Injections Market Share & Competitive Landscape

The market combines large pharmaceutical companies, specialized HA suppliers, orthobiologic platform providers, and diversified orthopedic-device companies. The five leading suppliers - Zimmer Biomet, Ferring, Pfizer, Sanofi, and Bioventus - collectively account for approximately 56.2% of global market revenue. Pfizer represents approximately 23.5% through its corticosteroid franchise. The competitive basis differs by modality: HA suppliers compete on dosing convenience, reimbursement, and clinical evidence; PRP suppliers compete on reproducibility and provider workflow; regenerative-therapy developers compete on clinical differentiation and regulatory execution.

Anika Therapeutics markets HA products including Monovisc and Orthovisc and is developing Cingal, an HA-triamcinolone hexacetonide combination. Anika reported USD 26.2 million in first-quarter 2025 revenue from continuing operations and described progress in its Cingal and Hyalofast development programs.

Arthrex participates in orthobiologics through its autologous conditioned plasma and Angel PRP systems. Its strength is integration with orthopedic and sports-medicine physician networks, where PRP adoption depends on equipment training and procedural consistency.

Bioventus offers a one-, three-, and five-injection HA portfolio through DUROLANE, Gelsyn-3, and Supartz FX. Its 2023 results showed pain-treatment volume growth while also identifying Medicare reimbursement changes as an important commercial factor. The company's Aetna Medicare Advantage agreement for DUROLANE highlights its focus on payer access.

Cipla entered the advanced joint-injection category with Ciplostem, launched in India in December 2025 with Stempeutics Research. The product combines 25 million bone-marrow-derived mesenchymal stromal cells with HA for Grade II/III knee OA.

EmCyte Corporation supplies point-of-care PRP and bone-marrow-concentrate processing systems. Its position depends on the ability to provide high-concentration, repeatable preparations suitable for clinic and ASC use.

Recent Industry Developments

• December 2025 - Cipla launched Ciplostem in India. The allogeneic mesenchymal stromal cell therapy is co-administered with HA for Grade II/III knee OA.
• May 2025 - The FDA approved an EUFLEXXA PMA supplement. Supplement P010029/S041 authorized an alternate 160-liter intermediate vessel for manufacturing.
• July 2025 - Anika reported completion of the Phase III FastTRACK study for Hyalofast. The company described its final PMA-module filing plans in its development update.